RxDoctor Payments Data

Steven Shamosh, MD

Internal Medicine · Cooperstown, NYNPI 1265639116

Payments from drug & device makers

$10,841in general payments, 2019–2025

Across 242 payments — averaging $44.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Novo Nordisk$1K
  • GSK$1K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Pfizer$442
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$10,835100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,841 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$33,285
Medicare patients
93
Services billed
319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol27$39,681
JardianceEmpagliflozin20$19,886
OzempicSemaglutide16$18,573
EliquisApixaban18$13,576
DuleraMometasone/Formoterol12$3,916
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,592
Atorvastatin Calcium151$1,308
Albuterol Sulfate HfaAlbuterol Sulfate42$1,201
Pantoprazole Sodium67$1,069
Rosuvastatin Calcium65$1,053
Levothyroxine Sodium45$932
Potassium Chloride17$871
Losartan Potassium64$790
Metoprolol Succinate24$749
Amlodipine Besylate115$741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$3,545$39,68127 claims
Boehringer IngelheimJardiance$70$19,88620 claims
Novo NordiskOzempic$1,466$18,57316 claims
PfizerEliquis$442$13,57618 claims
MerckDulera$99$3,91612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Cooperstown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →